Learn more about UC TechAlerts – Subscribe to categories and get notified of new UC technologies

Browse Category: Medical > Therapeutics

Categories

[Search within category]

First-in-class Targeted Therapy for Acute Kidney Injury (AKI)

This invention provides the first-in-class targeted therapy for acute kidney injury (AKI) by systemically administering protein WFDC2.

Small Molecule Pendrin Inhibitors for Treatment of Inflammatory Airway Diseases and Diuretic Resistance

Small molecule pendrin inhibitors for treating inflammatory lung diseases.

Novel Small Molecule Drug for the Treatment of Constipation and Oxalate Kidney Stones

UCSF researchers have developed a novel small molecule drug that specifically targets and inhibits SLC26A3 (DRA), an anion exchanger whose inhibition is expected to have therapeutic benefit in constipation and oxalate kidney stone disease.

Chimeric Antigen Receptors For Phagocytosis (Car-P)

UCSF researchers have engineered a chimeric antigen receptor for phagocytosis (CAR-P) that promotes engulfment of cancer cells.

Novel Tumor-targeting Virus for Cancer Therapy

UCSF researchers have developed a novel engineered virus that specifically targets tumor cells using a knottin moiety, to effectively eliminate a number of cancer types.

NOVEL TUMOR SELECTIVE INTERNALIZING ANTIBODIES

Novel human monoclonal antibodies recognize a cell surface antigen that has limited normal tissue expression but is highly overexpressed in several types of cancers, including mesothelioma, melanoma, head and neck cancer, lung cancer, glioblastoma multiforme, pancreatic cancer, ovarian cancer, breast cancer, prostate cancer, cervical cancer, skin cancer and testicular cancer. The antibodies can block tumor invasion, self-renewal and have potential to modulate immune effector cell function.

Novel Gut Microbiome-based Diagnostic and Therapeutic for Neonates at Risk of Childhood Atopy and Asthma

UCSF researchers have developed a novel gut microbiome-based diagnostic test and targeted treatment for early-life identification of atopy or asthma risk in children.

Potent TMEM16A Small Molecule Treatment for Inflammatory and Reactive Airway Diseases, Asthma, Hypertension, Pain and Cancer

A novel class of 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides (AACTs) as potent TMEM16A inhibitors

The Use Of Parathyroid Gland Cells And Their Secreted Factors To Promote Islet Beta Cell Engraftments

This invention identifies a novel method to increases survival of transplanted islets in extra-hepatic sites (subcutaneous and intramuscular) through co-transplantation of pancreatic islet beta cells together with parathyroid glands (PTGs). This treatment can successfully be used for patients with type I diabetes.

Combination Hormone Therapy for Multiple Sclerosis

This invention identifies FDA-approved selective estrogen receptor modulators (SERMs), that when used alone or in combination with estrogen promote remyelination and thus can potentially be used as therapeutics for multiple sclerosis (MS).

Novel Use of Chitinases for Treatment of Lung Inflammatory and Fibrotic Diseases

A novel approach for the treatment of lung inflammatory and fibrotic diseases by increased or repaired chitinase function in lung tissues

NOVEL BRAIN TECHNOLOGY FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS USING ELECTRICAL STIMULATIONS

This invention is a novel technology developed to treat a patient’s neurological and/or psychiatric conditions. It consists of a system of implantable devices and computational algorithms that not only has autonomous control in sensing and stimulation of electrical signals in the patient’s brain, but also enables interactions with the external environment, thereby enhancing training and learning.

A Potent and Selective FXIa Inhibitor as a Next-generation Antithrombotic Drug

UCSF partnered with Pfizer’s Centers for Therapeutic Innovation (CTI) to identify an IND-ready antibody directed towards the treatment of thrombotic disease. The asset is a fully human antibody targeting the coagulation cascade serine protease FXIa for currently underserved thrombotic disease indications. A potent reversal agent has also been developed.

Immunotherapy for Treatment of Neuromyelitis Optica (NMO)

This invention comprises compositions and methods for treatment of neuromyelitis optica (NMO) spectrum disorders using anti-aquaporin-4 (AQP4) antibody lacking effector function.

TREATING TYPE-1 DIABETES BY PRESERVING BETA CELL FUNCTION

This invention proposes the first pharmacological treatment to prevent the onset of Type I diabetes by preventing beta cell destruction. 

METHOD FOR DETECTING AND TREATING NASAL AND LUNG DYSBIOSIS PATIENTS WITH MICROORGANISMS

This invention uses sequencing of microbiota community for diagnosis and treatment of lung and nasal dysbiosis.

Bispecific Antibodies for Detection and Treatment of Cancers Associated with EGFR Overexpression

This invention identifies novel bispecific antibodies that can be used to detect and/or treat various cancers that overexpress EGFR family of proteins.

Antiviral Compounds for HIV and Other Viral Infections

This invention identifies a novel class of HIV inhibitors targeting RNA-protein interactions.

NOVEL SMALL MOLECULE COMPOUNDS AND TARGET FOR TREATMENT OF AIRWAY HYPERRESPONSIVENESS IN ASTHMA

Novel small molecule compounds that modulate a new target for the treatment of asthma. 

Novel Small Protein Inhibitors for Rapid and Controllable CRISPR-Cas9 Interference

This invention identifies a novel class of natural protein-based inhibitors of CRISPR-Cas9, which could eliminate off-target effects of Cas9-mediated gene editing. It also presents an attractive antibiotic strategy and a potential biodefense agent against CRISPR bioterror threat.

A Novel Method to Generate Specific and Permanent Macromolecular Covalent Inhibitors

UCSF researchers have invented a novel method to generate covalent macromolecular inhibitors. This strategy allows a peptide inhibitor to bind to its target protein specifically and irreversibly through proximity-enabled bioreactivity.

Protein Kinase C Epsilon Small Molecule Inhibitors to Treat Pain, Anxiety, Alcoholism, and Nicotine Addiction

This invention provides new inhibitors to protein kinase C epsilon (PKCε) for the treatment and prophylaxis of various diseases such as pain, anxiety, alcoholism, inflammation, cancer, diabetes, and other conditions.

A Mouse Model of Human Papillomavirus (HPV) infection for Drug Discovery

UCSF researchers have generated and validated a K14-HPV16 transgenic mouse model, in which transgene expression produces neoplastic progression that fully resembles the gynecological and other epithelial dysplastic lesions induced by high risk HPVs. This model offers an invaluable tool for studying HPV infection and developing new drugs for HPV treatment.

Repurposing Dabuzalgron to Prevent and Treat Cardiomyopathy and Heart Failure

Using an alpha-1A-adrengic receptor agonist, dabuzalgron, as a therapeutic treatment for cardiomyopathy and heart failure.

A Novel Therapeutic Against HIV Using Human T Cell Immunoglobulin Mucin (TIM-3) Ligands to Modulate Immune Response

Blocking human T cell immunoglobulin and mucin domain-containing molecule 3 (TIM-3) signaling can restore functionality to defective T cells in HIV-1 infected patients. Additionally, measuring TIM-3 provides clinicians with a novel way of evaluating, staging, and monitoring the progression of HIV infections.

  • Go to Page: